查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1454246

支气管扩张剂的全球市场：按药物类别、给药途径、适应症、分销管道和地区划分。

Global Bronchodilators Market, By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Geography .
出版日期: | 出版商: Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，全球支气管扩张剂市值为228.5亿美元，预计2031年将达到304.4亿美元，2024年至2031年的年复合成长率（CAGR）预计将成长3.6%。

报告范围 报告详情
基准年 2023年 2023/2024年市场规模 228.5亿美元
实际资料 2019-2023 预测期 2024-2031
预测期2023/2024~2030/2031年复合成长率： 3.60% 2030/2031价值预测 304.4亿美元
图 1. 2023 年支气管扩张剂的全球市场占有率(%)（按地区）
全球支气管扩张剂市场-IMG1

支气管扩张剂是扩张肺部气道以使呼吸更容易的药物。支气管扩张剂的作用是放鬆和扩张支气管周围的平滑肌，减少喘息、咳嗽、气短以及与气喘和慢性阻塞性肺病(COPD) 等呼吸系统疾病相关的其他症状。支气管扩张剂包括短效药物和长效药物，前者用于短期缓解突然发作的呼吸困难，后者用于控制气喘和慢性阻塞性肺病的呼吸困难，并抵消皮质类固醇对气喘的影响。提升的版本。抗胆碱能药物（也称为抗毒蕈碱药）主要用于治疗慢性阻塞性肺病，但有些也可用于治疗气喘。抗胆碱能药物透过阻断胆碱能神经来扩大气道。支气管扩张剂的副作用因特定药物而异。支气管扩张剂的常见副作用包括手部颤抖、头痛、肌肉痉挛、噁心和呕吐以及腹泻等。

市场动态：

全球支气管扩张剂市场的成长是由于老年人口的增加（更容易患呼吸道疾病）、都市区和农村地区环境污染水平的上升以及对气喘和慢性阻塞性肺病（COPD）正确管理的认识等因素造成的。例如增加然而，替代治疗方案的可用性、长期使用支气管扩张剂相关的副作用、重磅药物的专利到期等是预期抑制市场成长的一些主要因素。联合治疗的开拓，即可以同时施用两种或多种药物，正在为该市场的参与者创造新的机会。此外，越来越重视预防性吸入疗法以更好地管理呼吸道症状可能会推动未来的需求。

本研究的主要特点

  • 该报告详细分析了全球支气管扩张剂市场，并提供了以2023年为基准年的预测期（2024-2031）的市场规模和年复合成长率（CAGR%）。
  • 它还说明了各个细分市场的潜在商机，并为该市场提供了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
  • 主要公司简介包括 GSK plc.、AstraZeneca、Mylan NV、Merck &Co, Inc.、Sun Pharmaceutical Industries Ltd.、Glenmark Pharmaceuticals Limited、Novartis AG、Boehringer Ingelheim International GmbH、Teva Pharmaceutical Industries Ltd.、Cipla Inc.、Sunovion Ingelheim International GmbH、Teva Pharmaceutical Industries Ltd.、Cipla Inc.、Sunovion Ingelticals Inc. .、赛诺菲和Innoviva。
  • 该报告的见解使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
  • 全球支气管扩张剂市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 透过用于分析全球支气管扩张剂市场的各种策略矩阵，将有助于相关人员做出决策。

目录

第一章 研究目的与前提

  • 研究目标
  • 先决条件
  • 简称

第二章 市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第三章市场动态、法规及趋势分析

  • 市场动态
    • 增加产品核准
    • 严格的法规环境
    • 加强宣传宣传活动
  • 主要亮点
  • 监管场景
  • 市场趋势
  • 管道分析
  • 产品发布/核准
  • PEST分析
  • 波特的分析
  • 流行病学
  • 治疗流程（病人历程）
  • 治疗方案分析
  • 主要市场参与者的新投资
  • 价格分析
  • 疾病意识计划
  • 治疗安全性和有效性分析
  • 合併、收购和合作

第四章全球支气管扩张剂市场－冠状病毒（COVID-19）大流行的影响

  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 供需面分析
  • 经济影响

第五章全球支气管扩张剂市场，依药物类别，2019-2031

  • β-肾上腺素能支气管扩张剂
  • 黄嘌呤衍生物
  • 抗胆碱能支气管扩张剂

第六章全球支气管扩张剂市场，依给药途径，2019-2031

  • 口服
  • 鼻腔（吸入）
  • 注射

第 7 章 全球支气管扩张剂市场，依适应症划分，2019-2031 年

  • 气喘
  • 慢性阻塞性肺病（COPD）
  • 其他（慢性支气管炎等）

第8章全球支气管扩张剂市场，依通路，2019-2031

  • 医院药房
  • 零售药房
  • 网路药房

第9章全球支气管扩张剂市场，按地区，2019-2031

  • 北美洲
  • 美国
  • 加拿大
  • 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第10章竞争格局

  • 公司简介
    • GSK plc.
    • Mylan NV
    • Mylan NV
    • Merck &Co., Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Glenmark Pharmaceuticals Limited
    • Novartis AG
    • Boehringer Ingelheim International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Inc.
    • Sunovion Pharmaceuticals Inc.
    • Sanofi
    • Innoviva

第11章 章节

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI6679

The global bronchodilators market was valued US$ 22.85 Bn in 2023 and is expected to reach US$ 30.44 Bn by 2031, growing at a compound annual growth rate (CAGR) of 3.6% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2023/2024: US$ 22.85 Bn
Historical Data for: 2019 to 2023 Forecast Period: 2024 - 2031
Forecast Period 2023/2024 to 2030/2031 CAGR: 3.60% 2030/2031 Value Projection: US$ 30.44 Bn
Figure 1. Global Bronchodilators Market Share (%), By Region, 2023
Global Bronchodilators Market - IMG1

Bronchodilators are medications that help open up the airways in the lungs to allow for easier breathing. They work by relaxing and dilating the smooth muscles surrounding the bronchial tubes, thus reducing wheezing, coughing, shortness of breath and other symptoms associated with respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be either short-acting used as short-term relief from sudden, unexpected attacks of breathlessness or long-acting used regularly to help control breathlessness in asthma and COPD, and increase the effectiveness of corticosteroids in asthma. Anticholinergics (also known as antimuscarinics) are mainly used to treat COPD, but a few can also be used for asthma. Anticholinergics cause the airways to widen by blocking the cholinergic nerves. The side effects of bronchodilators can vary, depending on the specific medication. General side effects of bronchodilators include trembling, particularly in the hands, headache, muscle cramps, nausea and vomiting, diarrhea, etc.

Market Dynamics:

The global bronchodilators market growth is driven by factors such as the growing geriatric population which is more susceptible to respiratory diseases, increased environmental pollution levels in both urban and rural areas, and rising awareness about proper management of asthma and COPD. However, availability of alternative treatment options, side effects associated with long term use of bronchodilators, and patent expires of blockbuster drugs are some of the key factors expected to restrain market growth. Development of combination therapies that can deliver two or more drugs simultaneously is opening new opportunities for players in this market. Moreover, greater emphasis on preventive inhalation therapies for better management of respiratory symptoms will drive future demand.

Key features of the study:

  • This report provides in-depth analysis of the global bronchodilators market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global bronchodilators market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies - Key companies covered as a part of this study include GSK plc., AstraZeneca, Mylan N.V., Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Novartis AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Inc., Sunovion Pharmaceuticals Inc., Sanofi and Innoviva
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global bronchodilators market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bronchodilators market

Detailed Segmentation:

  • Global Bronchodilators Market, By Drug Class
    • Beta-adrenergic Bronchodilators
    • Xanthine Derivatives
    • Anticholinergic Bronchodilators
  • Global Bronchodilators Market, By Route of Administration
    • Oral
    • Nasal (inhalable)
    • Injectable
  • Global Bronchodilators Market, By Indication
    • Asthma
    • Chronic Obstructive Pulmonary Disease (COPD)
    • Others (Chronic bronchitis, etc.)
  • Global Bronchodilators Market, By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Bronchodilators Market, By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa
  • Top Companies in the Global Bronchodilators Market:
    • GSK plc.
    • AbbVie Inc.
    • AstraZeneca
    • Mylan N.V.
    • Merck & Co., Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Glenmark Pharmaceuticals Limited
    • Novartis AG
    • Boehringer Ingelheim International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Inc.
    • Sunovion Pharmaceuticals Inc.
    • Sanofi
    • Innoviva

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Indication
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing Product Approval
    • Stringent Regulatory Environment
    • Increasing Awareness Campaigns
  • Key Highlights
  • Regulatory Scenario
  • Market Trends
  • Pipeline Analysis
  • Product Launch/Approval
  • PEST Analysis
  • PORTER's Analysis
  • Epidemiology
  • Treatment Algorithm (Patient Journey)
  • Treatment Option Analysis
  • New Investments by Major Market Players
  • Pricing Analysis
  • Disease Awareness Programs
  • Treatment Safety and Efficacy Analysis
  • Mergers, Acquisitions, and Collaborations

4. Global Bronchodilators Market- Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Bronchodilators Market, By Drug Class, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Beta-adrenergic Bronchodilators
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Xanthine Derivatives
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Anticholinergic Bronchodilators
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

6. Global Bronchodilators Market, By Route of Administration, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Nasal (inhalable)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

7. Global Bronchodilators Market, By Indication, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Asthma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Chronic Obstructive Pulmonary Disease (COPD)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Others (Chronic bronchitis, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

8. Global Bronchodilators Market, By Distribution Channel, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2020 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 201s9-2031, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (US$ Bn)

9. Global Bronchodilators Market, By Region, 2019-2031, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Country, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Country, 2020 -2031
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031, (US$ Bn)
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

  • Company Profile
    • GSK plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
    • Mylan N.V.
    • Merck & Co., Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Glenmark Pharmaceuticals Limited
    • Novartis AG
    • Boehringer Ingelheim International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Inc.
    • Sunovion Pharmaceuticals Inc.
    • Sanofi
    • Innoviva
  • Analyst Views

11. Section

  • References
  • Research Methodology
  • About us